GLENN SBLENDORIO - 02 Nov 2022 Form 4 Insider Report for IVERIC bio, Inc. (ISEE)

Role: CEO, Director
Signature: /s/ Todd D.C. Anderman, as Attorney-in-Fact for Glenn P. Sblendorio
Issuer symbol: ISEE
Transactions as of: 02 Nov 2022
Transactions value $: -$1,150,500
Form type: 4
Filing time: 04 Nov 2022, 17:01:40 UTC
Previous filing: 10 Jun 2022
Next filing: 13 Dec 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ISEE	Common Stock	Sale	-$1.15M	-50K	-21.77%	$23.01	180K	02 Nov 2022	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. The sales reported on this Form 4 are the final shares to be sold under the above referenced Rule 10b5-1 trading plan. This plan is now terminated.
F2	The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $22.54 to $23.65 per share on November 2, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.

Content

The exercises and sales reported on this form were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 11, 2021, as previously disclosed in the Registrant's Quarterly Report on Form 10-Q for the quarter ended September 30, 2021, as filed with the Securities and Exchange Commission on November 9, 2021, and as described in the Registrant's Proxy Statement for its 2022 Annual Meeting of the Stockholders, as filed with the Securities and Exchange Commission on March 30, 2022. The sales reported on this Form 4 are the final shares to be sold under the above referenced Rule 10b5-1 trading plan. This plan is now terminated.

The sale price of the Reporting Person's shares represents the weighted average price of all shares sold by a broker in multiple transactions effected at prices ranging from $22.54 to $23.65 per share on November 2, 2022. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Registrant or a security holder of the Registrant, information regarding the number of shares sold at each price within the range.